Zanubrutinib treatment in several blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This non-interventional study looks at outcomes for people with certain slow-growing blood cancers who are treated with zanubrutinib, with specific add-on use of obinutuzumab for follicular lymphoma. It may help doctors understand how this treatment is working in real-world care across several cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have one of these conditions: Waldenström’s macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma.
- Your prior treatment history must match the study rules: marginal zone lymphoma needs at least 2 prior treatments including an anti-CD20 antibody, and follicular lymphoma needs at least 3 prior treatments.
- Your doctor has already decided on treatment with zanubrutinib (and for follicular lymphoma, zanubrutinib plus obinutuzumab), following the official label (SmPC).
- You sign and date an informed consent form.
- You do NOT have a known reason you cannot take zanubrutinib based on the official label.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial tests a targeted therapy called zanubrutinib for people aged 80 and older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It may help control the disease with fewer side effects than standard chemotherapy.
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
Hear when a new Waldenström's Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.